Atlas market file · Equity · United States
Arbutus Biopharma CorpABUS
- Last close
- 4.62
- Change
- +4.52%
- 96-bar range
- 4.01 – 5.38
- As of
- 5 Aug 2026
Arbutus Biopharma Corp is a pharmaceutical preparations issuer listed as ABUS on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
ABUS
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+18.77% over the window).
Source rail: Yahoo Finance chart API (ABUS). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for ABUS. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
ABUS public profile
Pharmaceutical preparations issuer. Arbutus Biopharma Corp is connected to current market context, cited company sources and its retained research file.
Arbutus Biopharma Corp trades as ABUS on NASDAQ. Arbutus Biopharma Corp (ABUS) has a latest verified close of 4.62, up 4.52%, dated 5 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files ABUS under USA Stocks and Healthcare & Medicine Stocks for browsing.
ABUS technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on ABUS
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep ABUS research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
ABUS FAQ
What is Arbutus Biopharma Corp (ABUS)?Arbutus Biopharma Corp (ABUS) has a latest verified close of 4.62, up 4.52%, dated 5 Aug 2026. Use this page to check the price chart, company context, source-backed...
Arbutus Biopharma Corp (ABUS) has a latest verified close of 4.62, up 4.52%, dated 5 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for ABUS?Arbutus Biopharma Corp (ABUS) has a latest verified close of 4.62, up 4.52%, dated 5 Aug 2026. It brings the latest available chart, company context, cited sources,...
Arbutus Biopharma Corp (ABUS) has a latest verified close of 4.62, up 4.52%, dated 5 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files ABUS under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the ABUS page updated?The ABUS public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The ABUS public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for ABUS?The ABUS file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ABUS. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The ABUS file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ABUS. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on ABUS?Yes. The workstation can open a research path for ABUS from the public symbol record and then pull the available public sources for the fuller report.
Yes. The workstation can open a research path for ABUS from the public symbol record and then pull the available public sources for the fuller report.
Is this ABUS page investment advice?No. The ABUS page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The ABUS page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-07-24. Browse FreedomCore Atlas research notes →